Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is an intractable, though rare,
complication in cancer patients with bone metastases and patients with osteoporosis who …

Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

Background Antiresorptive agents such as bisphosphonates and denosumab, as well as
angiogenesis inhibitors, may induce medication-related osteonecrosis of the jaw (MRONJ) …

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of
antiresorptive and antiangiogenic agents, and it is also a potentially painful and debilitating …

OBJECTIVE: Medication-related osteonecrosis of the jaw (MRONJ) is a severe drug-related
side effect mostly seen in the maxillofacial region of patients under current or previous …

Background: Nearly two decades have passed since a paradoxical reaction in the orofacial
region to some bone modifying agents and other drugs was recognized, namely medication …

Medication-related osteonecrosis of the jaw (MRONJ) occurs in patients undergoing oral
surgery while medicated with bisphosphonate, denosumab or anti-angiogenic agents. We …

Bisphosphonates (BPs) are medications widely used in clinical practice to treat osteoporosis
and reduce fragility fractures. Its beneficial effects on bone tissue have been consolidated in …

We studied the effectiveness of teriparatide (TPTD) for treating medication-related
osteonecrosis of the jaw (MRONJ) in patients with osteoporosis and examined differences in …

Medication-related osteonecrosis of the jaw (MRONJ) is a complex disease which can be
associated with multiple morbidities and is challenging to treat. This review evaluates the …